title: Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
abstract: OBJECTIVE
  To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.
  
  
  METHODS
  Systematic review and meta-analysis of randomised controlled trials.
  
  
  METHODS
  Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting.
  
  
  RESULTS
  12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients (0.43, 0.32 to 0.59).
  
  
  CONCLUSIONS
  Fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome.
authors.affiliation: Gastroenterology Division, McMaster University, Health Sciences Centre, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada. alexf12399@yahoo.com
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Ford
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Talley
authors.forename: Brennan M R
authors.initials: BM
authors.lastname: Spiegel
authors.forename: Amy E
authors.initials: AE
authors.lastname: Foxx-Orenstein
authors.forename: Lawrence
authors.initials: L
authors.lastname: Schiller
authors.forename: Eamonn M M
authors.initials: EM
authors.lastname: Quigley
authors.forename: Paul
authors.initials: P
authors.lastname: Moayyedi
mesh_terms: D000328:Adult; D004043:Dietary Fiber / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000628:therapy*; D036142:Mentha piperita; D010276:Parasympatholytics / Q000627:therapeutic use*; D010938:Plant Oils / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States
chemical_list: D004043:Dietary Fiber; D010276:Parasympatholytics; D010938:Plant Oils; C015424:peppermint oil